CureVac and partner GSK are, meanwhile, also developing an mRNA-based flu vaccine, but are a little further back in development, as their shot is in phase 1 testing.
A Canadian teen who is in critical condition after contracting H5N1 bird flu was infected with a version of the virus that is different from the one circulating in U.S. cattle.